Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5094 participants.

Also called NCT03252249

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,094 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03252249
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
New Zealand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03252249. Randomized; no masking; primary purpose treatment. Start 2018-04-26 (actual); primary completion 2023-02-04 (actual). Results posted on 2026-01-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
Condition
Acute Coronary Syndrome
Intervention (Other)
3 months dual anti-platelet therapy
Intervention (Other)
12 months dual anti-platelet therapy
Lead sponsor
University of Edinburgh (class: other)
Collaborator
British Heart Foundation (class: other)

Record details

Record id
cardio:ct-nct03252249
Content hash
41d15b96eb859c87a8c26f402e61af69cc93662d1147a847e83109ccafee4630